Information Provided By: 
Fly News Breaks for July 26, 2017
ZTS
Jul 26, 2017 | 10:01 EDT
Cleveland Research analyst Rob Stuyck expects Zoetis to report Q2 upside driven by increasing demand for Simparica and Apoquel and improved U.S. vet hospital traffic. The analyst is forecasting Q2 earnings of 54c, ahead of consensus of 53c, and maintains a Buy rating.
News For ZTS From the Last 2 Days
ZTS
Apr 23, 2024 | 05:05 EDT
Barclays lowered the firm's price target on Zoetis to $230 from $260 and keeps an Overweight rating on the shares ahead of the Q1 report. The analyst expects the Q1 reports to provide continuing evidence of improvement in generics and biosimilars for the specialty pharmaceuticals group.
